Skip to main content

Table 1 Characteristics of included studies in meta-analysis

From: Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis

Author Year Country Ethnicity Treatment Follow-up (month) Cut-off Study period Patients (n) Survival analysis NOS score
Mehmet Aliustaoglu 2010 Turkey Caucasian Chemotherapy NA 160 2004–2008 168 OS 7
Deshen Wang 2012 China Asian Surgery 39.9 (23.77–57.43) 150/300 2006–2009 324 OS/DFS 8
Suee Lee 2013 Korea Asian Chemotherapy 14.9 (1–47.9) 160 2007–2010 174 OS 7
Qing Wang 2014 China Asian Mixed NA 160 2006–2014 439 OS 7
Dawei Yuan 2014 China Asian Surgery NA 150 2009–2012 280 OS/DFS 7
Nan Jiang 2014 China Asian Surgery 42 (1–103) 184 2005–2007 377 OS 8
Lian Lian 2015 China Asian Surgery 60 208 2007–2010 162 OS/DFS 8
Fen Wang 2015 China Asian Chemotherapy 40 235 2010–2011 120 NA 6
KaiYu Sun 2015 China Asian Surgery 55.75 (0.8–186) 140 1998–2008 632 OS 8
Xuechao Liu 2015 China Asian Surgery NA 180 2015–2010 455 OS 7
Meral Gunaldi 2015 Turkey Caucasian Mixed 11.5 160 NA 245 OS 6
M. Messager 2015 UK Caucasian Surgery 31.8 (4–131) 192 2001–2014 153 OS/DFS 8
Qiwen Deng 2015 China Asian Surgery 24 (3–60) 132 2007–2009 389 OS/DFS 8
Jun-Te Hsu 2015 China Asian Surgery 30 132 2005–2011 1030 OS 8
Eun Young Kim 2015 Korea Asian Surgery NA 126 2000–2009 1986 OS/DFS 7
Aldemir(1) 2015 Turkey Caucasian Surgery NA 170 2006–2013 53 OS 7
Aldemir(2) 2015 Turkey Caucasian Chemotherapy NA 170 2006–2013 50 OS 7
Wenyang Pang 2016 China Asian Surgery NA 155.67 2009–2011 492 NA 6
Xin Zhou 2016 China Asian Surgery NA 167 2006–2008 451 OS 7
Jin Wang 2016 China Asian Chemotherapy NA 201.6 2005–2013 273 OS 7
Neng Lou 2017 China Asian Surgery NA 106 2006–2014 312 NA 6
Weipeng Gong 2017 China Asian Surgery 22 (8–67) 161 2007–2015 91 OS 8
Kenichi Inaoka 2017 Japan Asian Surgery NA 71 1999–2016 312 NA 6
Masayuki Urabe 2017 Japan Asian Surgery 63.3 NA 1999–2014 1363 OS/DFS 8
Shubin Song 2017 China Asian Surgery 37 (3–108) 139.12 2007–2011 1990 OS 8
Fan Feng(1) 2017 China Asian Surgery 24.9 (1–75) 130.675 2008–2015 1621 OS 8
Fan Feng(2) 2017 China Asian Surgery 24.9 (1–75) 130.675 2008–2015 1622 OS 8
Kenji Mima Tsu 2017 Japan Asian Surgery NA 200 2006–2016 33 OS 7
Kang Wang 2017 China Asian Surgery 45 (1–185) 120 1994–2005 444 OS 8
Harry E. Fuentes 2017 USA Caucasian Mixed 21.3 (9.5–42.6) 260 2010–2015 112 OS 7
Mikito Mori 2018 Japan Asian Surgery 37 (5–108) 149.4 2006–2017 100 NA 7
Hongtai Shi 2018 China Asian Surgery 36 (1–75) 135 2012–2014 688 OS 8
YuChen Pan 2018 China Asian Surgery 59.9 115 2008–2012 870 OS 8
Guangsheng Zhu 2018 China Asian Surgery NA 117.78 2010–2016 248 OS 7
Hai-Jeon Yoon 2018 Japan Asian Surgery 34.5 (6.5–74.8) 10.1 2011–2016 134 OS/DFS 8
Yan Zhang 2018 China Asian Mixed NA 172 2011–2014 182 OS/DFS 7
Ji lin 2018 China Asian Surgery NA 116.85 2015–2016 670 OS 7
A. Ramos-Esquivel 2018 Costa Rica Caucasian Mixed 13.21 (0–84) 350 2009–2012 381 OS/DFS 7
Jiaxin Wen 2018 UK Caucasian Surgery NA 150 2003–2015 668 OS 7
Angelica Petrillo 2018 Italy Caucasian Chemotherapy 29 (20.4–37.5) 157 2010–2017 151 OS 8
Hiroaki Saito 2018 Japan Asian Surgery NA 173.3 2005–2013 453 OS 7
Cheng Tang 2018 China Asian Surgery NA 130.7 2010–2016 104 OS 7
Li-xiang Zhang 2018 China Asian Surgery NA 160 2010–2011 904 OS 7
Osama Abu-Shawer 2019 Jordan Asian Mixed NA 150 NA 447 OS 7
Xinran Zhang 2019 China Asian Surgery 44.9 (1–188.9) 168.5 2000–2010 2752 OS 8
Cuixia Liu 2019 China Asian Surgery NA 152.2 2009–2012 400 NA 6
Hua-Long Zheng 2019 China Asian Surgery 54 (35–67) 133.03 2009–2013 924 OS 8
Yuka Ohe 2020 Japan Asian Chemotherapy NA 180 2005–2018 41 OS 7
Ibrahim Mungan 2020 Turkey Caucasian Surgery NA 181.8 2015–2018 292 NA 6
Jian-Xian Lin 2020 China Asian Surgery 65.6 (1–117) 162.5 2009–2014 2257 OS 8
Guanghui Zhao 2020 China Asian Chemotherapy 11.6 143.39 2012–2016 110 OS 8
  1. NA not available, OS overall survival, DFS disease-free survival, NOS Newcastle-Ottawa Scale